Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
2000 1
2011 1
2012 3
2013 2
2014 5
2015 5
2016 11
2017 14
2018 14
2019 11
2020 13
2021 13
2022 18
2023 23
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
A national precision cancer medicine implementation initiative for Norway.
Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public–Private Partnership Consortium; Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R; InPreD-Norway and National Molecular Tumor Board Consortium; IMPRESS-Norway Consortium; Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å. Taskén K, et al. Nat Med. 2022 May;28(5):885-887. doi: 10.1038/s41591-022-01777-4. Nat Med. 2022. PMID: 35513529 No abstract available.
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures.
Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K, Galinsky J, Giesinger JM, Holzner B, Le Cessie S, O'Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A; SISAQOL-IMI Consortium. Pe M, et al. Among authors: falk rs. Lancet Oncol. 2023 Jun;24(6):e270-e283. doi: 10.1016/S1470-2045(23)00157-2. Lancet Oncol. 2023. PMID: 37269858 Free article. Review.
Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice.
Liu L, Choi J, Musoro JZ, Sauerbrei W, Amdal CD, Alanya A, Barbachano Y, Cappelleri JC, Falk RS, Fiero MH, Regnault A, Reijneveld JC, Sandin R, Thomassen D, Roychoudhury S, Goetghebeur E, le Cessie S; SISAQOL-IMI Work Package 3. Liu L, et al. Among authors: falk rs. Lancet Oncol. 2023 May;24(5):e197-e206. doi: 10.1016/S1470-2045(23)00110-9. Lancet Oncol. 2023. PMID: 37142381 Review.
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.
Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA. Røssevold AH, et al. Among authors: falk rs. Nat Med. 2022 Dec;28(12):2573-2583. doi: 10.1038/s41591-022-02126-1. Epub 2022 Dec 8. Nat Med. 2022. PMID: 36482103 Free PMC article. Clinical Trial.
The Oslo Ischaemia Study: cohort profile.
Falk RS, Mariampillai JE, Prestgaard EE, Heir T, Bodegård J, Robsahm TE, Grundvold I, Skretteberg PT, Engeseth K, Bjornholt JV, Stavem K, Liestøl K, Sandvik L, Thaulow E, Erikssen G, Kjeldsen SE, Gjesdal K, Erikssen JE. Falk RS, et al. BMJ Open. 2021 Oct 13;11(10):e049111. doi: 10.1136/bmjopen-2021-049111. BMJ Open. 2021. PMID: 34645662 Free PMC article.
Statistical advising: Professional development opportunities for the biostatistician.
LeBlanc M, Rueegg CS, Bekiroğlu N, Esterhuizen TM, Fagerland MW, Falk RS, Frøslie KF, Graf E, Heinze G, Held U, Holst R, Lange T, Mazumdar M, Myrberg IH, Posch M, Sergeant JC, Vach W, Vance EA, Weedon-Fekjaer H, Zucknick M. LeBlanc M, et al. Among authors: falk rs. Stat Med. 2022 Feb 28;41(5):847-859. doi: 10.1002/sim.9290. Stat Med. 2022. PMID: 35194815 Free PMC article. No abstract available.
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M, Ünal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L, Mootien J, Johannessen A, Møller JH, Pollan BD, Tveita AA, Kildal AB, Richard JC, Dalgard O, Simensen VC, Baldé A, de Gastines L, Del Álamo M, Aydin B, Lund-Johansen F, Trabaud MA, Diallo A, Halvorsen B, Røttingen JA, Tacconelli E, Yazdanpanah Y, Olsen IC, Costagliola D; EU SolidAct study group. Trøseid M, et al. Crit Care. 2023 Jan 10;27(1):9. doi: 10.1186/s13054-022-04205-8. Crit Care. 2023. PMID: 36627655 Free PMC article. Clinical Trial.
Comparing the use of patient-reported outcomes in clinical studies in Europe in 2008 and 2018: a literature review.
Astrup GL, Rohde G, Rimehaug SA, Andersen MH, Bernklev T, Bjordal K, Falk RS, Jørgensen NMH, Stavem K, Tollisen A, Amdal CD; on behalf of PROMiNET. Astrup GL, et al. Among authors: falk rs. Qual Life Res. 2022 Mar;31(3):659-669. doi: 10.1007/s11136-021-02946-7. Epub 2021 Aug 4. Qual Life Res. 2022. PMID: 34350566 Free PMC article. Review.
126 results